Filing Flows › Health Care › Scienture Holdings (SCNX)
Scienture Holdings (SCNX) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Scienture Holdings (SCNX) Q2 2026 earnings results →
Q2 2026 821¢ of every $1 of revenue lost · operating margin -785.6%
Scienture Holdings made $344K in Q2 2026. Operating margin -785.6%, net loss $2.8M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $344K in Q2 2026, up 510% from the previous quarter.
Gross margin was 97.7%. Operating costs exceeded revenue by $2.7M, an operating margin of -785.6%. The quarter ended with a net loss of $2.8M, narrower than the previous quarter's $3.4M loss.
Operating cash flow was −$3.1M. Non-cash charges added back $462K of depreciation and amortization and $103K of share-based compensation. Working capital and other items used $875K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $344K | — | -785.6% | −$2.8M | −$3.1M |
| Q1 2026 | 10-Q | May 15, 2026 | $56K | +449% | n/m | −$3.4M | −$2.9M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $590K | +810% | -739.1% | −$3.6M | −$3.2M |
| Q1 2025 | 10-Q | May 12, 2025 | $10K | — | n/m | −$3.1M | −$3.0M |
| Q4 2024 | 10-K | Mar 26, 2025 | $53K | -59% | n/m | −$7.2M | −$2.9M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Scienture Holdings
SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com .
In its own words, from its 8-K, filed Aug 20, 2026.
Scienture Holdings against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Operating margin: -785.6% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| SCNX Scienture Holdings | Q2 2026 | $344K | — | -785.6% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Scienture Holdings 10-Q on SEC EDGAR · CIK 1382574 · Pharmaceutical Preparations
More on SCNX
History
Every quarter: Q2 2026 results · Q1 2026 results · Q3 2025 results · Q1 2025 results · Q4 2024 results